Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 3/20 | 0.51 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12424455 | 0.95 | BCHE (0.51) | BCHERIPK1DPP4RAB9ACYP46A1 | |
| SCHEMBL483677 | 0.93 | BCHE (0.50) | BCHERIPK1DPP4RAB9AKDM4E | |
| SCHEMBL2964616 | 0.91 | — | — | |
| SCHEMBL14557436 | 0.87 | BCHE (0.43) | BCHERIPK1DPP4RAB9ACYP46A1 | |
| SCHEMBL17793148 | 0.83 | RIPK1 (0.43) | BCHERIPK1MTNR1AMTNR1BKDM4E | |
| SCHEMBL23520795 | 0.83 | BCHE (0.42) | BCHERIPK1DPP4RAB9ACYP46A1 | |
| SCHEMBL15199087 | 0.83 | BCHE (0.42) | BCHERIPK1DPP4RAB9ACYP46A1 | |
| SCHEMBL15199086 | 0.83 | BCHE (0.42) | BCHERIPK1DPP4RAB9ACYP46A1 | |
| SCHEMBL15200292 | 0.81 | BCHE (0.41) | BCHERIPK1DPP4CYP46A1KDM4E | |
| SCHEMBL5988184 | 0.81 | BCHE (0.41) | BCHERIPK1DPP4CYP46A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210236442-A1 | METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES | DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) | 2021-08-05 | — | — | US | disclosed |
| US-20130281476-A1 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2013-10-24 | — | — | US | disclosed |
| EP-1951660-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007049123-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281476-A1 | Modulators of Muscarinic Receptors | CHRM3, CHRM5, CHRM2 | BCHE 243/4885RIPK1 2068/4885DPP4 1478/4885 |
| US-20210236442-A1 | METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES | IAPP, SLC5A2, SLC2A2 | BCHE 2412/4885RIPK1 3869/4885DPP4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.